Mobocertinib CAS# 1847461-43-1 莫博替尼/TAK-788
Mobocertinib, also known as TAK-788 and AP32788, is an investigational TKI with potent, selective preclinical activity against activating EGFR and HER2 mutations, including exon 20 insertions. TAK-788 exhibits antitumor activity in pts with EGFR exon 20 insertions with an AE profile consistent with other EGFR TKIs.
📌 参考资料/链接：
Insight into Targeting Exon20 Insertion Mutations of the Epidermal Growth Factor Receptor with Wild Type-Sparing InhibitorsBy: Lategahn, Jonas ; et alJournal of Medicinal Chemistry (2022), 65(9), 6643-6655
Insight into Targeting Exon20 Insertion Mutations of the Epidermal Growth Factor Receptor with Wild Type-Sparing InhibitorsBy: Lategahn, Jonas ; et alJournal of Medicinal Chemistry (2022), 65(9), 6643-6655
📄 详细内容
CAS No. 1847461-43-1 莫博替尼/TAK-788Mobocertinib synthetic routes
Insight into Targeting Exon20 Insertion Mutations of the Epidermal Growth Factor Receptor with Wild Type-Sparing InhibitorsBy: Lategahn, Jonas ; et alJournal of Medicinal Chemistry (2022), 65(9), 6643-6655
产品链接: CAS No. 1847461-43-1 ››
Insight into Targeting Exon20 Insertion Mutations of the Epidermal Growth Factor Receptor with Wild Type-Sparing InhibitorsBy: Lategahn, Jonas ; et alJournal of Medicinal Chemistry (2022), 65(9), 6643-6655
产品链接: CAS No. 1847461-43-1 ››